Wells Fargo analyst David Maris noted weakness in shares of Mylan today, which he thinks may be in part due to the delay for generic Advair announced on Wednesday, but also in part due to comments quoted yesterday by Bloomberg from the head of Mylan's European business, Jacek Glinka. Glinka was said to indicate that price erosion is prevalent across all countries in Europe, with Bloomberg saying that he stated Mylan is "feeling like a lemon which is squeezed by two hands." Maris thinks severe pricing declines in generics have been most recently considered a U.S. phenomenon and Glinka's comments raised caution about Europe as well. He maintains a Market Perform rating on Mylan shares.